PMID- 19036619
OWN - NLM
STAT- MEDLINE
DCOM- 20100114
LR  - 20131121
IS  - 1532-2130 (Electronic)
IS  - 1090-3798 (Linking)
VI  - 13
IP  - 6
DP  - 2009 Nov
TI  - Safety of botulinum toxin type A in children younger than 2 years.
PG  - 511-5
LID - 10.1016/j.ejpn.2008.10.006 [doi]
AB  - BACKGROUND: Botulinum toxin type A (BoNT-A) has been used in many indications and 
      is licensed for the treatment of spasticity in children older than 2 years. 
      However, there are few reports of BoNT-A treatment in patients younger than 2 
      years of age. AIMS: To review retrospectively the safety data from all infants 
      treated with botulinum toxin type A (BoNT-A) before 2 years of age in a 
      paediatric neurology unit. METHODS: There were 74 infants: 28 received the first 
      dose before 1 year of age, and 46 between the ages of 1 and 2 years. RESULTS: In 
      the first year of life, the most frequent indication was obstetric brachial palsy 
      (OBP) (71.4% of cases) and in the second year, cerebral palsy (CP) (73.9%). Both 
      Botox and Dysport, the two commercially-available BoNT-A products in Spain, were 
      used. The average starting dose by session was 6.55 U/kg body weight Botox in 
      infants in their first year of life, and 8.4 U/kg body weight Botox and 21.1 U/kg 
      body weight Dysport in the second year of life. Only 3.6% of cases treated in the 
      first year and 6.5% of those treated in the second experienced adverse events 
      (AEs), which consisted of mild weakness or tiredness lasting 1-4 days. 
      CONCLUSIONS: BoNT-A has a good safety profile in infants younger than 2 years 
      old. AEs are similar to those found in older children.
FAU - Pascual-Pascual, Samuel Ignacio
AU  - Pascual-Pascual SI
AD  - Pediatric Neurology Service, University Hospital La Paz, Paseo de la Castellana 
      261, 28046 Madrid, Spain. ipascualp.hulp@salud.madrid.org
FAU - Pascual-Castroviejo, Ignacio
AU  - Pascual-Castroviejo I
LA  - eng
PT  - Journal Article
DEP - 20081125
PL  - England
TA  - Eur J Paediatr Neurol
JT  - European journal of paediatric neurology : EJPN : official journal of the 
      European Paediatric Neurology Society
JID - 9715169
RN  - 0 (Neuromuscular Agents)
RN  - EC 3.4.24.69 (Botulinum Toxins, Type A)
SB  - IM
MH  - Botulinum Toxins, Type A/*adverse effects/therapeutic use
MH  - Cerebral Palsy/drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*chemically induced
MH  - Humans
MH  - Infant
MH  - Neuromuscular Agents/*adverse effects/therapeutic use
MH  - Paralysis, Obstetric/drug therapy
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Spain
MH  - Spasm/drug therapy
MH  - Treatment Outcome
EDAT- 2008/11/28 09:00
MHDA- 2010/01/15 06:00
CRDT- 2008/11/28 09:00
PHST- 2008/06/28 00:00 [received]
PHST- 2008/09/28 00:00 [revised]
PHST- 2008/10/07 00:00 [accepted]
PHST- 2008/11/28 09:00 [pubmed]
PHST- 2010/01/15 06:00 [medline]
PHST- 2008/11/28 09:00 [entrez]
AID - S1090-3798(08)00191-8 [pii]
AID - 10.1016/j.ejpn.2008.10.006 [doi]
PST - ppublish
SO  - Eur J Paediatr Neurol. 2009 Nov;13(6):511-5. doi: 10.1016/j.ejpn.2008.10.006. 
      Epub 2008 Nov 25.